George W. Kosturko

Array ( [id] => 20676354 [patent_doc_number] => 20260115163 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-04-30 [patent_title] => NOVEL TREATMENTS [patent_app_type] => utility [patent_app_number] => 19/427233 [patent_app_country] => US [patent_app_date] => 2025-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6924 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19427233 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20568466 [patent_doc_number] => 20260062387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-03-05 [patent_title] => SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME [patent_app_type] => utility [patent_app_number] => 19/383969 [patent_app_country] => US [patent_app_date] => 2025-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55062 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19383969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20598961 [patent_doc_number] => 20260076964 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-03-19 [patent_title] => METHOD OF TREATING SCLC AND MANAGING HEPATOTOXICITY [patent_app_type] => utility [patent_app_number] => 19/336350 [patent_app_country] => US [patent_app_date] => 2025-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45444 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 147 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19336350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20471930 [patent_doc_number] => 20260014148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-15 [patent_title] => METHOD OF TREATING SCLC AND MANAGING NEUTROPENIA [patent_app_type] => utility [patent_app_number] => 19/336341 [patent_app_country] => US [patent_app_date] => 2025-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45728 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19336341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20598962 [patent_doc_number] => 20260076965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-03-19 [patent_title] => METHOD OF TREATING SCLC AND MANAGING THROMBOCYTOPENIA [patent_app_type] => utility [patent_app_number] => 19/336364 [patent_app_country] => US [patent_app_date] => 2025-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45630 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19336364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20419102 [patent_doc_number] => 20250381187 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-18 [patent_title] => KRAS G12C INHIBITORS AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 19/312046 [patent_app_country] => US [patent_app_date] => 2025-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 184406 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19312046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20406343 [patent_doc_number] => 20250375452 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-11 [patent_title] => SOTORASIB DOSING REGIMEN [patent_app_type] => utility [patent_app_number] => 19/309299 [patent_app_country] => US [patent_app_date] => 2025-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19309299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20715328 [patent_doc_number] => 12630562 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-19 [patent_title] => Piperidylurea compounds and methods of use thereof [patent_app_type] => utility [patent_app_number] => 19/290944 [patent_app_country] => US [patent_app_date] => 2025-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62333 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19290944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20320031 [patent_doc_number] => 20250332119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-30 [patent_title] => NOVEL ANTI-INFLAMMATORY COMPOSITION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/265100 [patent_app_country] => US [patent_app_date] => 2025-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19265100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20465354 [patent_doc_number] => 12521383 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-13 [patent_title] => Stable pharmaceutical compositions of apixaban [patent_app_type] => utility [patent_app_number] => 19/207781 [patent_app_country] => US [patent_app_date] => 2025-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 12111 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19207781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20163827 [patent_doc_number] => 20250255873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-14 [patent_title] => RESTORING FUNCTION OF SPECIFIC MUTATIONS AFFECTING THE ACTIN DYNAMIC BY ADMINISTRATION OF SAPROPTERIN [patent_app_type] => utility [patent_app_number] => 19/182228 [patent_app_country] => US [patent_app_date] => 2025-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19182228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19798889 [patent_doc_number] => 20250064814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => FORMULATION PRODUCTION PROCESS [patent_app_type] => utility [patent_app_number] => 18/946234 [patent_app_country] => US [patent_app_date] => 2024-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18946234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19798901 [patent_doc_number] => 20250064826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => NASAL COMPOSITIONS COMPRISING ALCAFTADINE [patent_app_type] => utility [patent_app_number] => 18/943165 [patent_app_country] => US [patent_app_date] => 2024-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18943165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19798900 [patent_doc_number] => 20250064825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => NASAL COMPOSITIONS COMPRISING ALCAFTADINE [patent_app_type] => utility [patent_app_number] => 18/943124 [patent_app_country] => US [patent_app_date] => 2024-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18943124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19815033 [patent_doc_number] => 20250073240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => NEW TREATMENT [patent_app_type] => utility [patent_app_number] => 18/825447 [patent_app_country] => US [patent_app_date] => 2024-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18825447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19599429 [patent_doc_number] => 20240390309 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => ANTIVIRAL COMPOSITIONS AND METHODS FOR INACTIVATING NON-ENVELOPED VIRUSES USING ALKYL 2-HYDROXYCARBOXYLIC ACIDS [patent_app_type] => utility [patent_app_number] => 18/790166 [patent_app_country] => US [patent_app_date] => 2024-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15687 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18790166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19743925 [patent_doc_number] => 20250032490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => THERAPEUTIC REGIMENS FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA [patent_app_type] => utility [patent_app_number] => 18/784478 [patent_app_country] => US [patent_app_date] => 2024-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30923 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18784478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19601043 [patent_doc_number] => 20240391923 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER [patent_app_type] => utility [patent_app_number] => 18/784600 [patent_app_country] => US [patent_app_date] => 2024-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18784600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20951141 [patent_doc_number] => 20260258009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-09-03 [patent_title] => 3-[(BENZO[D][1,3]DIOXOLANE-4-YL)OXY]PROPYLAMINE HYDROCHLORIDE, OPTICAL ISOMER AND CRYSTAL THEREOF, AND PREPARATION METHOD THEREFOR [patent_app_type] => utility [patent_app_number] => 18/832316 [patent_app_country] => US [patent_app_date] => 2023-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18832316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19541641 [patent_doc_number] => 20240358677 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => LASOFOXIFENE TREATMENT OF AROMATASE-RESISTANT ER+ CANCER [patent_app_type] => utility [patent_app_number] => 18/764277 [patent_app_country] => US [patent_app_date] => 2024-07-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18764277 [rel_patent_id] =>[rel_patent_doc_number] =>)